Three Growth Companies Insiders Are Investing In

In This Article:

As global markets continue to rally, with U.S. stocks reaching record highs amid optimism for softer tariffs and AI investments, growth stocks have notably outperformed value shares for the first time this year. In such a buoyant market environment, companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

Archean Chemical Industries (NSEI:ACI)

22.9%

41.2%

Duc Giang Chemicals Group (HOSE:DGC)

31.4%

25.7%

Seojin SystemLtd (KOSDAQ:A178320)

32.1%

39.9%

Clinuvel Pharmaceuticals (ASX:CUV)

10.4%

26.2%

SKS Technologies Group (ASX:SKS)

29.7%

24.8%

Laopu Gold (SEHK:6181)

36.4%

36.6%

Medley (TSE:4480)

34.1%

27.3%

Plenti Group (ASX:PLT)

12.7%

120.1%

Fine M-TecLTD (KOSDAQ:A441270)

17.2%

135%

HANA Micron (KOSDAQ:A067310)

18.2%

119.4%

Click here to see the full list of 1482 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Ocumension Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ocumension Therapeutics, along with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China, with a market cap of HK$3.54 billion.

Operations: The company's revenue segment focuses on discovering, developing, and commercializing ophthalmic therapies, generating CN¥310.29 million.

Insider Ownership: 20.4%

Ocumension Therapeutics is positioned for significant growth, with revenue forecasted to increase 33.8% annually, outpacing the Hong Kong market. Despite past shareholder dilution, earnings are expected to grow over 100% per year and become profitable within three years. Recent executive changes include Dr. Qin Xie's appointment as a non-executive director, bringing extensive industry expertise. The company’s key drug candidate OT-301 is progressing through phase III trials in China and the US, indicating potential future market impact.

SEHK:1477 Earnings and Revenue Growth as at Jan 2025
SEHK:1477 Earnings and Revenue Growth as at Jan 2025

PharmaBlock Sciences (Nanjing)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: PharmaBlock Sciences (Nanjing), Inc. offers chemistry products and services for pharmaceutical research, development, and commercial production, with a market cap of CN¥6.21 billion.

Operations: The company's revenue from its drug research and development and production-related business amounts to CN¥1.56 billion.